Dual ligands targeting dopamine D2 and serotonin 5-HT 1A receptors as new antipsychotical or anti-parkinsonian agents

Current Medicinal Chemistry

Volumn 21, Issue 4, 2014, Pages 437-457

  Ye, Na ^a   Song, Zilan ^a   Zhang, Ao ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Atypical antipsychotics; Dopamine D2 receptor; Dual ligands; Parkinson's disease; Schizophrenia; Serotonin 5 HT1A receptor

Indexed keywords

2 AMINOTETRALIN DERIVATIVE; ADOPRAZINE; ANTIPARKINSON AGENT; APORPHINE DERIVATIVE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CARIPRAZINE; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LASSBIO 664; LIGAND; MAZAPERTINE; PARDOPRUNOX; PF 217830; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SARIZOTAN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; NEUROBIOLOGY; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DOPAMINE; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84893304140     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660300     Document Type: Article

References (185)

1. Meltzer, H. Y. Clinical studies on the mechanism of action of clozapine, the dopamine serotonin hypothesis of schizophrenia. Psychopharmacology, 1989, 99, S18-S27. (Pubitemid 19244134)
2. Meltzer, H. Y. The role of serotonin receptor antagonism: the action of atypical antipsychotic drugs. In: serotonin in the central nervous system and periphery; Tanaka, A., Curzon, G., Eds., Elsevier Science: New York, 1995; pp 169-174.
3. (a) Meltzer, H. Y.; Matsubara, S.; Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi Values. J. Pharmacol. Exp. Ther., 1989, 251, 238-246
4. Stockmeier, C. A.; DiCarlo, J. J.; Zhang, Y.; Thompson, P.; Meltzer, H. Y. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin 2 and dopamine 2 receptors. J. Pharmacol. Exp. Ther., 1993, 266, 1374-1384. (Pubitemid 24175781)
5. Love, R. C.; Nelson, M. W. Pharmacology and clinical experience with risperidone. Expert Opin. Pharmacother., 2000, 1, 1441-1453.
6. Nyberg, S.; Farde, L.; Eriksson, L.; Halldin, C.; Eriksson, B. 5- HT2 and D2 dopamine receptor occupancy in the living human brain: A PET study with risperidone. Psychopharmacology (Berlin), 1993, 110, 265-272. (Pubitemid 23051126)
7. Bhana, N.; Foster, R. H.; Olney, R.; Plosker, G. L. Olanzapine: an update review of its use in the management of schizophrenia. Drugs, 2001, 61, 111-161 (Pubitemid 32108327)
8. Nyberg, S.; Farde, L.; Halldin, C. A. PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology, 1997, 16, 1-7. (Pubitemid 27030990)
9. Brown, L. A.; Levin, G. M. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. Pharmacotherapy, 1998, 18, 69-83. (Pubitemid 28059006)
10. Kane, J. M. Sertindole: a review of clinical efficacy. Int. Clin. Psychopharmacol., 1998, 13, S59-S63.
11. Kasper, S.; Tauscher, J.; Heiden, A. Quetiapine: efficacy and tolerability in schizophrenia. Eur. Neuropsychopharmacol., 2001, S4, S405-413.
12. Kasper, S., Muller-Spahn, F. Review of quetiapine and its clinical applications in schizophrenia. Exp. Opin. Pharmacother., 2000, 1, 783-801.
13. Gunasekara, N. S.; Spencer, C. M.; Keating, G. M. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs, 2002, 62, 1217-1251. (Pubitemid 34587577)
14. Lieberman, J. A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs, 2004, 18, 251-267. (Pubitemid 38393435)
15. Wolf, W. A. SLV-308. Solvay. Curr. Opin. Investig. Drugs, 2003, 4, 878-882.
16. Schapira, A. H.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G. L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Le Novere, N.; Obeso, J. A.; Schwarzschild, M. A.; Spampinato, U.; Davidai, G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov., 2006, 5, 845-854. (Pubitemid 44480538)
17. Kvernmo, T.; Houben, J.; Sylte, I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr. Top. Med. Chem., 2008, 8, 1049-1067.
18. Kehne, J. H.; Andree, T. H.; Heinrich, J. N. D2 receptor partial agonists: treatment of CNS disorders of dopamine function. Curr. Top. Med. Chem., 2008, 8, 1068-1088.
19. Lacivita, E.; Leopoldo, M.; Berardi, F.; Perrone, R. 5-HT1A receptor, an old target for new therapeutic agents. Curr. Top. Med. Chem., 2008, 8, 1024-1034.
20. Etievant, A.; Bétry, C.; Haddjeri, N. Partial dopamine D2/serotonin 5-HT1A receptor agonists as new therapeutic agents. Open Neuropsychopharmacol. J., 2010, 3, 1-12.
21. Ohno, Y. New Insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders. Cent. Nerv. Syst. Agents Med. Chem., 2010, 10, 148-157.
22. Newman-Tancredi, A.; Kleven, M. S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl), 2011, 216, 451-473.
23. Jones, C. A.; McCreary, A. C. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology, 2008, 55, 1056-1065.
24. Meltzer, H. Y.; Massey, B. W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharm., 2011, 11, 59-67.
25. Andreasen, N. C. Schizophrenia: the fundamental questions. Brain Res. Rev., 2000, 31, 106-112. (Pubitemid 30136166)
26. Evans, K.; McGrath, J.; Milns, R. Searching for schizophrenia in ancient Greek and Roman literature: a systematic review. Acta. Psych. Scand., 2003, 107, 323-330. (Pubitemid 36606148)
27. Rossler, W.; Salize, H. J.; van Os, J.; Riecher-Rossler, A. Size of burden of schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol., 2005, 15, 399-409. (Pubitemid 40943544)
28. Delay, J.; Deniker, P.; Harl, J. M. Utilisation en thérapeutique psychiatrique d'une phénothiazine d'action centrale élective (4560 RP). Ann. Med. Psychol.(Paris), 1952, 110, 112-117.
29. Carlsson, A.; Lindqvist, M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta. Pharmacol. Toxicol., 1963, 20, 140-144.
30. Davis, J. M.; Chen, N.; Glick, I. D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiat., 2003, 60, 553-564. (Pubitemid 36682312)
31. (a) Leucht, S.; Wahlbeck, K.; Hamann, J.; Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, 2003, 361, 1581-1589. (Pubitemid 36578993)
32. Mojtabai, R., Lavelle, J.; Gibson, P. J.; Bromet, E. J. Atypical antipsychotics in first admission schizophrenia: medication continuation and outcomes. Schizophr. Bull., 2003, 29, 519-530. (Pubitemid 37339386)
33. Abbas, A.; Roth, B. L. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin. Pharmacother., 2008, 9, 3251-3259.
34. (a) Fermini, B.; Fossa, A. A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov., 2003, 2, 439-447 (Pubitemid 37361725)
35. Michelsen, J. W.; Meyer, J. M.; Cardiovascular effects of antipsychotics. Expert Rev. Neurother., 2007, 7, 829-839 (Pubitemid 47037723)
36. Titier, K.; Girodet, P. O.; Verdoux, H.; Molimard, M.; Begaud, B.; Haverkamp, W.; Lader, M.; Moore, N. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Safety, 2005, 28, 35-51.
37. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multitarget drugs: the network approach might help drug design. Trends Pharmacol. Sci., 2005, 26, 178-182 (Pubitemid 40432652)
38. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov., 2004, 3, 353-359. (Pubitemid 38499762)
39. Wong, E. H.; Yocca, F.; Smith, M. A.; Lee, C. M. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. Int. J. Neuropsychopharmacol., 2010, 13, 1269-1284.
40. Nasrallah, H. A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry, 2008, 13, 27-35. (Pubitemid 350275185)
41. Bantick, R. A.; Rabiner, E. A.; Hirani, E.; de Vries, M. H.; Hume, S. P.; Grasby, P. M. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacol., 2004, 29, 847-859. (Pubitemid 38528764)
42. Millan, M. J. Improving the treatment of schizophrenia: focus on serotonin 5-HT1A receptors. J. Pharmacol. Exp. Ther., 2000, 295, 853-861.
43. Newman-Tancredi, A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr. Opin. Investig. Drugs, 2010, 11, 802-812.
44. Newman-Tancredi, A.; Assié, M. B.; Martel, J. C.; Cosi, C.; Slot, L. B.; Palmier, C.; Rauly-Lestienne, I.; Colpaert, F.; Vacher, B.; Cussac, D. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile. Br. J. Pharmacol., 2007, 151, 237-252. (Pubitemid 46763035)
45. Sharma, R. P.; Shapiro, L. E. The 5-HT1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatr. Ann., 1996, 26, 88-93.
46. Liebman, J. M.; Gerhardt, S. C.; Gerber, R. Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology, 1989, 97, 456-461. (Pubitemid 19102545)
47. Ellenbroek, B. A., Prinssen, E. P.; Cools, A. R. The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur. J. Neurosci., 1994, 6, 1-8. (Pubitemid 24022660)
48. Porsolt, R. D.; Anton, G.; Blaver, N.; Jaffre, M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol., 1978, 47, 379-391.
49. (a) Ishibashi, T.; Ohno, Y. Antiparkinsonian actions of a selective 5-HT1A agonist, tandospirone, in rats. Biogenic Amines, 2004, 18, 329-338 (Pubitemid 39157398)
50. Wadenberg, M. L.; Young, K. A.; Richter, J. T.; Hicks, P. B. Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology, 1999, 38, 151-156 (Pubitemid 29073534)
51. Prinssen, E. P.; Colpaert, F. C.; Koek, W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur. J. Pharmacol., 2002, 453, 217-221. (Pubitemid 35223513)
52. Ohno, Y.; Shimizu, S.; Imaki, J.; Ishihara, S.; Sofue, N.; Sasa, M.; Kawai. Y. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32, 1302-1307
53. Ohno, Y.; Shimizu, S.; Imaki, J.; Ishihara, S.; Sofue, N.; Sasa, M.; Kawai, Y. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidolinduced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology, 2008, 55, 717-723
54. Ohno, Y.; Shimizu, S.; Imaki, J. Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J. Pharmacol. Sci., 2009, 109, 593-599.
55. Sumiyoshi, T.; Matsui, M.; Nohara, S.; Yamashita, I.; Kurachi, M.; Sumiyoshi, C.; Jayathilake, K.; Meltzer, H. Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry, 2001, 158, 1722-1725. (Pubitemid 32923670)
56. Sumiyoshi, T.; Park, S.; Jayathilake, K.; Roy, A.; Ertugrul, A.; Meltzer, H. Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, doubleblind, placebo-controlled study. Schizophr. Res., 2007, 95, 158-168 (Pubitemid 47313647)
57. Meltzer, H. Y.; Sumiyoshi, T. Does stimulation of 5-HT1A receptors improve cognition in schizophrenia? Behav. Brain. Res., 2008, 195, 98-102.
58. Lilienfeld, D. E.; Perl, D. P. Projected neurodegenerative disease mortality in the United States, 1990-2040. Neuroepidemiology, 1993, 12, 219-228. (Pubitemid 23353340)
59. (a) Schapira, A. H.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G. L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Le Novere, N.; Obeso, J. A.; Schwarzschild, M. A.; Spampinato, U.; Davidai, G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Disc., 2006, 5, 845-854. (Pubitemid 44480538)
60. Schapira, A. H. Future directions in the treatment of Parkinson's disease. Mov. Disord., 2007, 22, S385-S391. (Pubitemid 350134193)
61. Nagatsu, T.; Sawada, M. L-dopa therapy for Parkinson's disease: Past, present, and future. Parkinsonism Relat. Disord., 2009, 15, S3-S8.
62. Calabresi, P.; Di Filippo, M.; Ghiglieri, V.; Picconi, B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov. Disord., 2008, 23, S570-S579.
63. Abbott, A. Levodopa: The story so far. Nature, 2010, 466, S6-S7.
64. Yamamoto, M.; Schapira, A. H. Dopamine agonists in Parkinson's disease. Expert Rev. Neurother., 2008, 8, 671-677. (Pubitemid 351551017)
65. Rezak, M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis. Mon., 2007, 53, 214-222. (Pubitemid 46935688)
66. Abdel-Salam, O. M. Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol. Disord. Drug Targets, 2008, 7, 321-342.
67. Hornykiewicz, O. Brain monoamines and parkinsonism. Natl. Inst. Drug. Abuse Res. Monogr. Ser., 1975, 3. 13-21.
68. Santiago, M.; Matarredona, E. R.; Machado, A.; Cano, J. Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J. Neurosci. Res., 1998, 52, 591-598. (Pubitemid 28252740)
69. Melamed, E.; Hefti. F.; Wurtman, R. J. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann. Neurol. 1980, 8, 558-563. (Pubitemid 11213498)
70. Melamed, E.; Zoldan, J.; Friedberg, G.; Ziv, I.; Weizmann, A. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv. Neurol., 1996, 69, 545-550.
71. Meltzer, H. Y.; Nash, J. F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev., 1991, 43, 587-604.
72. Gerson, S. C.; Ross, J. B. Motor effects of serotonin in the central nervous system. Life Sci., 1980, 27, 1435-1451. (Pubitemid 11183077)
73. (a) Newman-Tancredi, A.; Assie, M. B.; Leduc, N.; Ormière, A.- M.; Danty, N.; Cosi, C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol., 2005, 8, 341-356 (Pubitemid 41002489)
74. Assie, M. B.; Ravailhe, V.; Faucillon, V.; Newman-Tancredi, A. Contrasting contribution of 5-HT1A receptor activation to neurochemical profile of novel antipsychotics: Frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther., 2005, 315, 265-272. (Pubitemid 41380520)
75. Bruins Slot, L. A.; De Vries, L.; Newman-Tancredi, A.; Cussac, D. Differential profile of antipsychotics at serotonin 5- HT1A and dopamine D2S receptors coupled to extracellular signalregulated kinase. Eur. J. Pharmacol., 2006, 534, 63-70. (Pubitemid 43384184)
76. Bruins Slot, L. A.; Kleven, M. S.; Newman-Tancredi, A. Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology, 2005, 49, 996-1006 (Pubitemid 41503299)
77. Kleven, M. S.; Barret- Grevoz, C.; Bruins Slot, L. A.; Newman-Tancredi, A. Novel antipsychotic agents with 5-HT1A agonist properties: Role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology, 2005, 49, 135-143 (Pubitemid 40933752)
78. Bantick, R. A.; Deakin, J. F.; Grasby, P. M. The 5-HT1A receptor in schizophrenia: A promising target for novel atypical neuroleptics? J. Psychopharmacol., 2001, 15, 37-46. (Pubitemid 32242102)
79. Feenstra, M. G.; Rollema, H.; Dijkstra, D.; Grol, C. J.; Horn, A. S.; Westerink, B. H. Effect of non-catecholic 2-aminotetralin derivatives on dopamine metabolism in the rat striatum. Naunyn-Schmied. Arch. Pharmacol., 1980, 313, 213-219. (Pubitemid 10010824)
80. Seiler, M. P., Markstein, R. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum. Mol. Pharmacol., 1984, 26, 452-457. (Pubitemid 15190707)
81. Beart, P. M.; Cook, C. J.; Cincotta, M.; de Vries, D. J.; Tepper, P.; Dijkstra, D.; Horn, A. S. Radioreceptor binding reveals the potencies of N,N-disubstituted 2-aminotetralins as D2 dopamine agonists. Naunyn-Schmied. Arch. Pharmacol., 1987, 336, 487-493. (Pubitemid 17166837)
82. Sonesson, C.; Boije, M.; Svensson, K.; Ekman, A.; Carlsson, A.; Romero, A. G.; Martin, I. J.; Duncan, J. N.; King, L. J.; Wikstroem, H. Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino) tetralins and the formation of active metabolites in vivo. J. Med. Chem., 1993, 36, 3409-3416. (Pubitemid 23335705)
83. Arvidsson, L. E.; Hacksell, U.; Nilsson, J. L.; Hjorth, S.; Carlsson, A.; Lindberg, P.; Sanchez, D.; Wikstroem, H. 8-Hydroxy-2-(di-npropylamino) tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J. Med. Chem., 1981, 24, 921-923. (Pubitemid 11015157)
84. Yu, H.; Liu, Y.; Malmberg, A. E.; Mohell, N.; Hacksell, U.; Lewander, T. Differential serotoninergic and dopaminergic activities of the (R)- and the (S)-enantiomers of 2-(di-n-propylamino)tetralin. Eur. J. Pharmacol., 1996, 303, 151-162.
85. Arvidsson, L.-E.; Hacksell, U.; Johansson, A. M.; Nilsson, J. L.; Lindberg, P.; Sanchez, D.; Wikstrom, H.; Svensson, K.; Hjorth, S.; Carlsson, A. 8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists. J. Med. Chem., 1984, 27, 45-51. (Pubitemid 14176375)
86. Arvidsson, L.-E.; Johansson, A. M.; Hacksell, U.; Nilsson, J. L.; Svensson, K.; Hjorth, S.; Magnusson, T.; Carlsson, A.; Andersson, B.; Wikstrom, H. (+)-cis-8- Hydroxy-l-methyl-2-(dipropy1amino) tetralin: A Potent and Highly Stereoselective 5-Hydroxytryptamine Receptor Agonist. J. Med. Chem., 1987, 30, 2105-2109. (Pubitemid 18046071)
87. Liu, Y.; Yu, H.; Mohell, N.; Nordvall, G.; Lewander, T.; Hacksell, U. Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists. J. Med. Chem., 1995, 38, 150-160.
88. Homan, E. J.; Copinga, S.; Elfstrom, L.; van der Veen, T.; Hallema, J. P.; Mohell, N.; Unelius, L.; Johansson, R.; Wikstrom, H. V.; Grol, C.J. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents. Bioorg. Med. Chem., 1998, 6, 2111-2126. (Pubitemid 28540759)
89. Homan, E. J.; Tulp, M. T.; Nilsson, J. E.; Wikstrom, H. V.; Grol, C. J. C5-substituted derivatives of 5-OMe-BPAT: synthesis and interactions with dopamine D2 and serotonin 5-HT1A receptors. Bioorg. Med. Chem., 1999, 7, 2541-2548. (Pubitemid 30122756)
90. Homan, E. J.; Kroodsma, E.; Copinga, S.; Unelius, L.; Mohell, N.; Wikstrom, H. V.; Grol, C. J. Structural analogues of 5-OMe- BPAT: synthesis and interactions with dopamine D2, D3, and serotonin 5-HT1A receptors. Bioorg. Med. Chem., 1999, 7, 1111-1121. (Pubitemid 29281613)
91. Glennon, R. A. Concepts for the Design of 5-HT1A Serotonin agonists and Antagonists. Drug Dev. Res., 1992, 26, 261-274.
92. Martin, E. G. Elgin, R. J.; Mathiaaen, J. R.; Davie, C. B.; Kdick, J. M.; Baldy, W. J.; Shank, R. P.; Di Stefano, D. L.; Fedde, C. L.; Scott, M. K. Activity of Aromatic Substituted Phenylpiperazinea Lacking Affiiity for Dopamine Binding Sites in a Preclinical Teat of Antipsychotic Efficacy. J. Med. Chem., 1989, 32, 1062-1056.
93. Van Wijngaarden, I.; Tulp, M. T.; Soudijn, W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmucol. Mol. Pharmacol. Sect., 1990, 188, 301-312. (Pubitemid 20188387)
94. Lowe, J. A.; Seeger, T. F.; Nagel, A. A.; Howard, H. R.; Seymour, P. A.; Heym, J. H.; Ewing, F. E.; Newman, M. E.; Schmidt, A. W.; Furman, J. S.; Vincent, L. A.; Maloney, P. R.; Robinson, G. L.; Reynolds, L. S.; Vinick, F. J. 1-Naphthylpiperazine Derivatives a Potent Atypical Antipsychotic Agents. J. Med. Chem., 1991, 34, 1860-1866.
95. Scott, M. K.; Martii, G. E.; Di Stefano, D. L.; Fedde, C. L.; Kukla, M. J.; Barrett, D. L.; Baldy, W. J.; Elgin, R. J.; Keeelick, J. M.; Mathiaeen, J. R.; Shank, R. P.; Vaught, J. L. Pyrrole Mannich bases as potential antipsychotic agents. J. Med. Chem., 1992, 35, 552-558.
96. Reitz, A. B.; Scott, M. K. Novel Antipsychotics with unique D2/5- HT1A affinity and minimal extrapyramidal side-effect liability. In Advances in Medicinal Chemistry; Maryanoff, B. E.; Maryanoff, C. A.; Eds.; JAI Press: Greenwich, 1995; Vol. 3, pp 1-56.
97. Scott, M. K.; Baxter, E. W.; Bennett, D. J.; Boyd, R. E.; Blum, P. S.; Codd, E. E.; Kukla, M. J.; Malloy, E.; Maryanoff, B. E.; Maryanoff, C. A.; Ortegon, M. E.; Rasmussen, C. R.; Reitz, A. B.; Renzi, M. J.; Schwender, C. F.; Shank, R. P.; Sherrill, R. G.; Vaught, J. L.; Villani, F. J.; Yim, N. Piperazinylalkyl Heterocycles as Potential Antipsychotic Agents. J. Med. Chem., 1995, 38, 4198-4210.
98. Reitz, A. B.; Baxter, E. W.; Bennett, D. J.; Codd, E. E.; Jordan, A. D.; Malloy, E. A.; Maryanoff, B. E.; McDonnell, M. E.; Ortegon, M. E.; Renzi, M. J., Scott, M. K., Shank, R. J., Sherrill, R. G., Vaught, J. L., Wustrow, D. J. N-Aryl-N-Benzylpiperazines as Potential Antipsychotic Agents. J. Med. Chem., 1995, 38, 4211-4222.
99. Reitz, A. B.; Baxter, E. W.; Codd, E. E.; Davis, C. B.; Jordan, A. D.; Maryanoff, B. E.; Maryanoff, C. A.; McDonnel, M. E.; Powell, E. T.; Renzi, M. J.; Schott, M. R.; Scott, M. K.; Shank, R. P.; Vaught, J. L. Orally Active Benzamide Antipsychotic Agents with Affinity for Dopamine D2, Serotonin 5-HT1A, and Adrenergic α1 Receptors. J. Med. Chem., 1998, 41, 1997-2009. (Pubitemid 28308617)
100. (a) Zhang, A.; Neumeyer, J. L.; Baldessarini, R. J. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem. Rev., 2007, 107, 274-302. (Pubitemid 46237370)
101. Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A. Recent Progress in the Development of Dopamine Receptor Subtype Compounds: Potential Therapeutic Agents for Neurological and Neuropsychiatric Disorders. Chem. Rev., 2013, 113, PR123-PR178.
102. Vaccher, M. P.; Lesieur, D.; Lespagnol, C.; Bonte, J. P.; Beaughard, M.; Dureng, G. Phenylethanolamines benzoxazolinoniques antagonistes des récepteurs adrénergiques. Etudes chimique et pharmacologique. Il Farmaco Ed. Sci., 1986, 41, 257-269 (Pubitemid 16083899)
103. Caignard, D. H.; Couquelet, J.; Lesieur, D.; Lespagnol, C.; Lamar, J. C.; Beaughard, M.; Leinot, M. Synthèse et étude pharmacologique d¢(Amino-2-éthyl)-6-benzoxazolinones. Il Farmaco Ed. Sci., 1985, 40, 854-868.
104. Glennon, R. A.; Naiman, R. A.; Lyon, R. A.; Titeler, M. Arylpiperazine Derivatives as High Affinity 5HT1A Serotonin Ligands. J. Med. Chem., 1988, 31, 1968-1971.
105. Mokrosz, J. L.; Strekowski, L.; Duszyuska, D.; Harden, D. B.; Mokrosz, M. J.; Bojarski, A. J. Structure-Affinity Relationship Studies of CNS Agents. Part 14: Structural Requirements for the 5HT1A and 5HT2A Receptor Selectivity of Simple 1-(2- Pyrimidyl)piperazine Derivatives. Pharmazie, 1994, 49, 801-806. (Pubitemid 24352504)
106. Taverne, T.; Diouf, O.; Depreux, P.; Poupaert, J. H.; Lesieur, D.; Guardiola-Lemaitre, B.; Renard, P.; Rettori, M. C.; Caignard, D. H.; Pfeiffer, B. Novel Benzothiazolin-2-one and Benzoxazin-3-one Arylpiperazine Derivatives with Mixed 5HT1A/D2 Affinity as Potential Atypical Antipsychotics. J. Med. Chem., 1998, 41, 2010-2018. (Pubitemid 28308618)
107. Favor, D. A.; Powers, J. J.; White, A. D.; Fitzgerald, L. W.; Groppi, V.; Serpa, K. A. 6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics. Bioorg. Med. Chem. Lett., 2010, 20, 5666-5669.
108. Johnson, D. S.; Choi, C.; Fay, L. K.; Favor, D. A.; Repine, J. T.; White, A. D.; Akunne, H. C.; et al. Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder. Bioorg. Med. Chem. Lett., 2011, 21, 2621-2625.
109. Roglic, G.; Andric, D.; Kostic-Rajacic, S.; Dukic, S.; Soskic, V. Introduction of a methyl group in alpha- or beta-position of 1- heteroarylethyl-4-phenylpiperazines affects their dopaminergic/serotonergic properties. Arch. Pharm. (Weinheim), 2001, 334, 375-380. (Pubitemid 34118729)
110. Andric, D.; Roglic, G.; Sukalovic, V.; Soskic, V.; Kostic-Rajacic, S. Synthesis, binding properties and receptor docking of 4-halo-6- [2-(4-arylpiperazin-1-yl) ethyl]-1H- benzimidazoles, mixed ligands of D2 and 5-HT1A receptors. Eur. J. Med. Chem., 2008, 43, 1696-705.
111. Andric, D.; Tovilkvic, G.; Roglic, G., Soskic, V.; Tomic, M.; Kostic- Rajacic, S. 6-[2-(4-arylpiperazin-1-yl)ethyl]-4-halo-1,3-dihydro- 2H-benzimidazole-2-thiones: synthesis and pharmacological evaluation. J. Ser. Chem. Soc., 2007, 72, 745-755.
112. Sukalovic, V.; Andric, D.; Roglic, G.; Kostic-Rajacic, S.; Schrattenholz, A.; Soskic, V. Synthesis, dopamine D2 receptor binding studies and docking analysis of 5-[3-(4-arylpiperazin-1-yl)propyl]- 1H-benzimidazole, 5-[2-(4-arylpiperazin- 1-yl)ethoxy]-1Hbenzimidazole and their analogs. Eur. J. Med. Chem., 2005, 40, 481-493. (Pubitemid 40693902)
113. Penjisevic, J.; Sukalovic, V.; Andric, D.; Kostic-Rajacic, S.; Soskic, V.; Roglic, G. 1-cinnamyl-4-(2-methoxyphenyl)piperazines: synthesis, binding properties, and docking to dopamine D2 and serotonin 5-HT1A receptors. Arch. Pharm. (Weinheim), 2007, 340, 456-465. (Pubitemid 47478066)
114. van Wijngaarden, I.; Kruse, C. G.; van Hes, R.; van der Heyden, J. A.; Tulp, M. T. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J. Med. Chem., 1987, 30, 2099-2104. (Pubitemid 18046070)
115. van Wijngaarden, I.; Kruse, C. G.; van der Heyden, J. A.; Tulp, M. T. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. J. Med. Chem., 1988, 31, 1934-1940.
116. Feenstra, R. W.; Visser, G. M.; Kruse, C. G.; Tulp, M. T.; Long, S. K. Piperazine and piperidine derivatives as 5-HT1 receptor agonists. E.P. Patent 0900792, March 10, 1999.
117. Feenstra, R. W.; de Moes, J.; Hofma, J. J.; Kling, H.; Kuipers, W.; Long, S. K.; Tulp, M. T.; van der Heyden, J. A.; Kruse, C. G. New 1-aryl-4-(biarylmethylene) piperazines as potential atypical antipsychotics sharing dopamine D2-receptor and serotonin 5-HT1Areceptor affinities. Bioorg. Med. Chem. Lett., 2001, 11, 2345-2349. (Pubitemid 32781696)
118. Protais, P.;Costentin, J.;Schwartz, J. C. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berlin), 1976, 50, 1-6.
119. Van der Heyden, J. A.; radford, D. A rapidly acquired one-way conditioned avoidance procedure in rats as a primary screening test for antipsychotics: influence of shock intensity on avoidance performance. Behav. Brain. Res., 1988, 31, 61-67.
120. Berendsen, H. H.;Jenck, F.;Broekkamp, C. L. Selective activation of 5-HT1A receptors induces lower lip retraction in the rat. Pharmacol. Biochem. Behav., 1989, 33, 821-827. (Pubitemid 19284295)
121. Feenstra, R. W.; van den Hoogenband, A.; Stroomer, C. N.; van Stuivenberg, H. H.; Tulp, M. T.; Long, S. K.; van der Heyden, J. A.; Kruse, C. G. SAR study of 1-aryl-4-(phenyl arylmethyl) piperazines as ligands for both dopamine D2 and serotonin 5-HT1A receptors showing varying degrees of (Ant)agonism. Selection of a potential atypical antipsychotic. Chem. Pharm. Bull. (Tokyo), 2006, 54, 1326-1230.
122. Neves, G.; Menegatti, R.; Antonio, C. B.; Grazziottin, L. R.; Vieira, R. O.; Rates, S. M.; Noel, F.; Barreiro, E. J.; Fraga, C. A. Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorg. Med. Chem., 2010, 18, 1925-1935.
123. Conrado, D. J.; Verli, H.; Neves, G.; Fraga, C. A.; Barreiro, E. J.; Rates, S. M.; Dalla Costa, T. Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. J. Pharm. Pharmacol., 2008, 60, 699.
124. McIntyre, J. A.; Castaner, J.; Bayes, M. Sarizotan hydrochloride. Antidyskinetic drug 5-HT1A receptor agonist dopamine D2 receptor ligand. Drugs Future, 2006, 31, 314-319.
125. Sorbera, L. A.; Castaner, J. Bifeprunox mesylate. Drugs Future, 2005, 30, 992-997.
126. (a) Thurkauf, A.; Yuan, J.; Chen, X.; Wasley, J. W.; Paneitz, G.; Meade, R.; Woodruff, K. H.; Huston, K.; Ross, P. C. 3- Aminomethylbiphenyls. A new class of dopamine receptor ligands. Med. Chem. Res., 1996, 6, 69-80. (Pubitemid 126443561)
127. Thurkauf. A.; Yuan, J.; Chen, X.; Wasley, J. W.; Meade, R.; Woodruff, K. H.; Huston, K.; Ross, P. C. 1-Phenyl-3-(aminomethyl) pyrroles as potential antipsychotic agents: Synthesis and dopamine receptor binding. J. Med. Chem., 1995, 38, 4950-4952.
128. Cuisiat, S.; Bourdiol, N.; Lacharme, V.; Newman-Tancredi, A.; Colpaert, F.; Vacher, B. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. J. Med. Chem., 2007, 50, 865-876. (Pubitemid 46332998)
129. (a) Evrard, D. A.; Zhou, P.; Yi, S. Y.; Zhou, D.; Smith, D. L.; Sullivan, K. M.; Hornby, G. A.; Schechter, L. E.; Andree, T. H.; Mewshaw, R. E. Studies towards the next generation of antidepressants. Part 4: Derivatives of 4-(5-fluoro-1H-indol -3-yl) cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor. Bioorg. Med, Chem. Lett., 2005, 15, 911-914 (Pubitemid 40458622)
130. Millan, M. J.; Gobert, A.; Newman-Tancredi, A.; Audinot, V.; Lejeune, F.; Rivet, J.-M.; Cussac, D.; Nicolas, J.-P.; Muller, O.; Lavielle, S. ((R)-2-{1- [2-(2,3-Dihydro-\benzo[1,4] dioxin-5-yloxy)- ethyl]-pyrrolidin- 3yl}-1-(4-fluorophenyl)ethanone, a novel, potential antipsychotic with marked serotonin 5-HT1A agonist properties: receptorial and neurochemical profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther., 1998, 286, 1341-1355. (Pubitemid 29135549)
131. Comoy, C.; Guerin, V.; Pfeiffer, B.; Rettori, M. C.; Renard, P.; Guillaumet, G.; Substituted 3-amino and/or 3-aminomethyl-3,4- dihydro-2H-1-benzopyrans: synthesis and biological activity. Bioorg. Med. Chem., 2000, 8, 483-495. (Pubitemid 30122354)
132. Lopez-Rodriguez, M. L.; Morcillo, M. J.; Fernandez, E.; Porras, E.; Orensanz, L.; Beneytez, M. E.; Manzanares, J.; Fuentes, J. A. Synthesis and structure-activity relationships of a new model of arylpiperazines. 5. Study of the physicochemical influence of the pharmacophore on 5-HT1A/α1-adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT1A/D2 antagonist properties. J. Med. Chem., 2001, 44, 186-197. (Pubitemid 32096663)
133. Andronati, S. A.; Soboleva, S. G.; Makan, S. Y.; Sava, V. M.; Kolodeev, G. E.; Voronina, T. A.; Molodavkin, G. M. Anxiolytic Properties of 1-Aryl-4-(phthalimidoalkyl)piperazines and Their Affinity to 5-HT1A Serotonin and D2 Dopamine Receptors. Pharma. Chem. J., 2003, 37, 15-18. (Pubitemid 37025247)
134. Asproni, B.; Pau, A.; Bitti, M.; Melosu, M.; Cerri, R.; Dazzi, L.; Seu, E.; Maciocco, E.; Sanna, E.; Busonero, F.; Talani, G.; Pusceddu, L.; Altomare, C.; Trapani, G.; Biggio, G. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4- imidazolyl) methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D2, serotonin, and GABAA receptors. J. Med. Chem., 2002, 45, 4655-4668.
135. (a) Harbert, C. A.; Plattner, J. J.; Welch, W. M.; Weissman, A.; Koe, B. K. Neuroleptic Activity in 5-Aryltetrahydro-ç-carbolines. J. Med. Chem., 1980, 23, 635-643
136. Abou-Gharbia, M. Biological Activity of Substituted β-Carbolines.
137. Paluchowska, M. H.; Mokrosz, M. J.; Charakchieva-Minol, S.; Duszynska, B.; Koziol, A.; Wesolowska, A.; Stachowicz, K.; Chojnacka- Wojcik, E. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4- tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity. Pol. J. Pharmacol., 2003, 55, 543-552. (Pubitemid 37185357)
138. Perrone, R.; Berardi, F.; Colabufo, N. A.; Tortorella, V.; Fiorentini, F.; Olgiati, V.; Vanotti, E.; Govoni, S. Mixed 5-HT1A/D2 Activity of a New Model of Arylpiperazines: 1-Aryl-4-[3-(1,2- dihydronaphthalen- 4-yl)-n-propyl] piperazines. 1. Synthesis and Structure-Activity Relationships. J. Med. Chem., 1994, 37, 99-104. (Pubitemid 24058818)
139. Perrone, R.; Bernrdi, F.; Tortorella, V.; Govoni, S.; Mano, M. D.; Daniele, E. Synthesis and dopamine receptor affinities of 1- aminoethylhetercttetralina. Eur. J. Med. Chem., 1991, 26, 869-874.
140. Perrone, R.; Berardi, F.; Ferorelli, S.; Tortorella, V.; Lograno, M. D.; Daniele, E.; Govoni, S. 8-Methoxy- and pdknethoxy-laminoethylhetercyclo synthesis and DA, 5-HT receptors affinities. II Farmaco, 1992, 47, 1285-1291. (Pubitemid 23005098)
141. Perrone. R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.; Tortorella, V. 1-Aryl-4-[(5- methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)alkyl] piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1- yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. J. Med. Chem., 1999, 42, 490-496. (Pubitemid 29085109)
142. Perrone, R.; Berardi, F.; Leopoldo, M.; Tortorella, V.; Fornaretto, M. G.; Caccia, C.; McArthur, R. 1-Aryl-4-[(1-tetralinyl)alkyl]- piperazines: alkylamido and alkylamino derivatives. Synthesis, 5- HT1A receptor affinity, and selectivity. J. Med. Chem., 1996, 39, 3195-3202.
143. Wustrow, D.; Belliotti, T.; Glase, S.; Kesten, S. R.; Johnson, D.; Colbry, N.; Rubin, R.; Blackburn, A.; Akunne, H.; Corbin, A.; Davis, M. D.; Georgic, L.; Whetzel, S.; Zoski, K.; Heffner, T.; Pugsley, T.; Wise, L. Aminopyrimidines with high affinity for both serotonin and dopamine receptors. J. Med. Chem., 1998, 41, 760-771. (Pubitemid 28114885)
144. Birch, A. M.; Bradley, P. A.; Gill, J. C.; Kerrigan, F.; Needham, P. L. N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D2 Antagonists /5-HT1A Partial Agonists with Potential as Atypical Antipsychotic Agents. J. Med. Chem., 1999, 42, 3342-3355. (Pubitemid 29409723)
145. Jurczyk, S.; Kolaczkowski, M.; Maryniak, E.; Zajdel, P.; Pawlowski, M.; Tatarczynska, E.; Klodzinska, A.; Chojnacka-Wojcik, E.; Bojarski, A. J.; Charakchieva-Minol, S.; Duszynska, B.; Nowak, G.; Maciag, D. New arylpiperazine 5-HT1A receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation. J. Med. Chem., 2004, 47, 2659-2666. (Pubitemid 38580102)
146. Zhang, J.; Zhang, H.; Cai, W.; Yu, L.; Zhen, X.; Zhang, A. 'Click' D1 receptor agonists with a 5-HT1A receptor pharmacophore producing D2 receptor activity. Bioorg. Med. Chem., 2009, 17, 4873-4880.
147. Matthiessen, A.; Wright, C. R. Researches into the Chemical Constitution of the Opium Bases. Part I. On the Action of Hydrochloric Acid on Morphia. Proc. R. Soc. Lond. Ser B, 1869, 17, 455-460.
148. (a) Goldman, M. E.; Kebabian, J. W. Aporphine enantiomers. Interactions with D1 and D2 dopamine receptors. Mol. Pharmacol., 1984, 25, 18-23. (Pubitemid 14223248)
149. Baldessarini, R. J.; Kula, N. S.; Zong, R.; Neumeyer, J. L. Receptor affinities of aporphine enantiomers in rat brain tissue. Eur. J. Pharmacol., 1994, 254, 199-203. (Pubitemid 24078713)
150. Zhang, A.; Zhang, Y.; Branfman, A. R.; Baldessarini, R. J.; Neumeyer, J. L. J. Med. Chem., 2007, 50, 171-181.
151. Liu, Z.; Zhang, H.; Ye, N.; Zhang, J.; Wu, Q.; Sun, P.; Li, L.; Zhen, X.; Zhang, A. Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist. J. Med. Chem., 2010, 53, 1319-1328.
152. Cannon, J. G.; Mohan, P.; Bojarski, J.; Long, J. P.; Bhatnagar, R. K.; Leonard, P. A.; Flynn, J. R.; Chatterjee, T. K. (R)-(-)-10- Methyl-11- hydroxyaporphine: a highly selective serotonergic agonist. J. Med. Chem., 1988, 31, 313-318. (Pubitemid 18045355)
153. Cannon, J. G.; Moe, S. T.; Long, J. P. Enantiomers of 11-hydroxy- 10-methyl aporphine having opposing pharmacological effects at 5- HT1A receptors. Chirality, 1991, 3, 19.
154. Hedberg, M. H.; Johansson, A. M.; Nordvall, G.; Yliniemela, A.; Li, H. B.; Martin, A. R.; Hjorth, S.; Unelius, L.; Sundell, S.; Hacksell, U. (R)-11-Hydroxy- and (R)-11-hydroxy-10-methylaporphine: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions. J. Med. Chem., 1995, 38, 647-658.
155. Hedberg, M. H.; Johansson, A. M.; Hacksell, U. J. Facile syntheses of aporphine derivatives. J. Chem. Soc. Chem. Commun., 1992, 11, 845-846.
156. Hedberg, M. H.; Jansen, J. M.; Nordvall, G.; Hjorth, S.; Unelius, L.; Johansson, A. M. 10-Substituted 11-Oxygenated (R)- Aporphines: Synthesis, Pharmacology, and Modeling of 5-HT1A Receptor Interactions. J. Med. Chem., 1996, 39, 3491-3502. (Pubitemid 26307854)
157. Hedberg, M. H.; Linnanen, T.; Jansen, J. M.; Nordvall, G.; Hjorth, S.; Unelius, L.; Johansson, A. M. 11-substituted (R)-aporphines: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions. J. Med. Chem., 1996, 39, 3503-3513. (Pubitemid 26307855)
158. Martin, L. P.; Cox, R. F.; Waszczak, B. L. Efficacy and potency comparisons among aporphine enantiomers: Effects on dopamine neurons in Substantia Nigra of rat. Neuropharmacology, 1990, 29, 135-143. (Pubitemid 20059589)
159. Csutoras, C.; Zhang, A.; Zhang, K.; Kula, N. S.; Baldessarini, R. J.; Neumeyer, J. L. Synthesis and neuropharmacological evaluation of R(-)-N-alkyl-11-hydroxy noraporphines and their esters. Bioorg. Med. Chem., 2004, 12, 3553-3559. (Pubitemid 38746857)
160. Liu, Z.; Chen, X.; Sun, P.; Yu, L.; Zhen, X.; Zhang, A. NPropylnoraporphin- 11-O-yl carboxylic esters as potent dopamine D2 and serotonin 5-HT1A receptor dual ligands. Bioorg. Med. Chem., 2008, 16, 8335-8338.
161. Zhang, H.; Ye, N.; Zhou, S.; Guo, L.; Zheng, L.; Liu, Z.; Gao, B.; Zhen, X.; Zhang, A. Identification of N-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl) pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile. J. Med. Chem., 2011, 54, 4324-4338.
162. Moon, M. W.; Morris, J. K.; Heier, R. F.; Chidester, C. G.; Hoffmann, W. E.; Piercey, M. F.; Althaus, J. S.; Von Voigtlander, P. F.; Evans, D. L.; Figur, L. M.; et al. Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds. J. Med. Chem., 1992, 35, 1076-1092.
163. Lahti, R. A.; Evana, D. L.; Figur, L. M.; Huff, R. M.; Moon, M. W. Pre- and Postsynaptic Dopaminergic Activities of U-86170F. Naunyn-Schmied. Arch. Pharm., 1991, 344, 509-513.
164. Von Voigtlander, P. F.; Althaus, J. S.; Camacho-ochoa, M.; Neff, G. L. Dopamine receptor agonist activity of U-66444B and it enantioiners: Evaluation of functional, biochemical, and pharmacokinetic properties. Drug Dev. Res., 1989, 17, 71-81. (Pubitemid 19162194)
165. Piercey, M. F.; Tang, A. H.; Lahti, R. A.; VonVoigtlander, P. F.; Schreur, P. J.; McCall, R. B.; Lum-Ragan, J. T.; Hoffmann, W. E.; Franklin, S. R.; Code, R. A.; et al. Pharmacology of a mixed 5- hydroxytryptamine1A/dopamine agonist. J. Pharmacol. Exp. Ther., 1994, 268, 1304-1310.
166. (a) Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Hirose, T.; Miwa, T.; Oshiro, Y.; Morita, S. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4- dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther., 1995, 274, 329-336.
167. Oshiro, Y.; Sato, S.; Kurahashi, N.; Tanaka, T.; Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Nishi, T. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7- [4-(4-phenyl-1- piperazinyl)-butoxy]-3,4-dihydro-2(1H)- quinolinone derivatives. J. Med. Chem., 1998, 41, 658-667. (Pubitemid 28114874)
168. Davies, M. A.; Sheffler, D. J.; Roth, B. L. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev., 2004, 10, 317-336. (Pubitemid 40128915)
169. McQuade, R. D.; Burris, K. D.; Jordan, S.; et al. Aripiprazole: a dopamine-serotonin system stabilizer. Int. J. Neuropsychopharmacol., 2002, 5, S176-S176.
170. Kinghorn, W. A., McEvoy, J. P. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev. Neurother., 2005, 5, 297-307. (Pubitemid 40705271)
171. Miller, D. D.; Eudicone, J. M.; Pikalov, A.; Kim, E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J. Clin. Psychiatry, 2007, 68, 1901-1906.
172. Kiss, B.; Horvath, A.; Nemethy, Z.; Schmidt, E.; Laszlovszky, I.; Bugovics, G.; Fazekas, K.; Hornok, K.; Orosz, S.; Gyertyan, I.; Agai-Csongor, E.; Domany, G.; Tihanyi, K.; Adham, N.; Szombathelyi, Z. Cariprazine (RGH-188), a dopamine D3 receptorpreferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther., 2010, 333, 328-340.
173. Gyertyan, I.; Kiss, B.; Saghy, K.; Laszlovszky, I.; Horvath, A.; Laszy, J.; Schmidt, E.; Szabo, G.; Domany, G.; Csongor, E. A.; Tihanyi, K.; Szombathelyi, Z. Pharmacological profile of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist atypical antipsychotic. Eur. Neuropsychopharmacol., 2006, 16, S432.
174. Glennon, J. C.; Van Scharrenburg, G.; Ronken, E.; Hesselink, M. B.; Reinders, J. H.; Van Der Neut, M.; Long, S. K.; Feenstra, R. W.; McCreary, A. C. In vitro characterization of SLV308 (7-[4- methyl-1-piperazinyl]-2(3H)- benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse, 2006, 60, 599-608. (Pubitemid 44658266)
175. Wolf, W. A. SLV-308. Solvay. Curr. Opin. Investig. Drugs. 2003, 4, 878-882.
176. Jones, C. A.; Johnston, L. C.; Jackson, M. J.; Smith, L. A.; van Scharrenburg G.; Rose, S.; Jenner, P. G.; McCreary, A. C. An in vivo pharmacological evaluation of pardoprunox (SLV308)-a novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease. Eur. Neuropsychopharmacol., 2010, 20, 582-593.
177. Newman-Tancredi, A.; Cussac, D.; Depoortere, R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr. Opin. Investig. Drugs, 2007, 8, 539-554. (Pubitemid 47016322)
178. Wolf, W. DU-127090 Solvay/H Lundbeck. Curr. Opin. Investig. Drugs, 2003, 4, 72-76.
179. Wadenberg, M.-L. Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors. Future Neurol., 2007, 2, 153-165. (Pubitemid 46805506)
180. Bartoszyk, G. D.; Van Amsterdam, C.; Greiner, H. E.; Rautenberg, W.; Russ, H.; Seyfried, C. A. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J. Neural. Transm., 2004, 111, 113-126. (Pubitemid 38283223)
181. Goetz, C. G.; Damier, P.; Hicking, C.; Laska, E.; Muller, T.; Olanow, C. W.; Rascol, O.; Russ, H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord., 2007, 22, S179-S186.
182. Reitz, A. B.; Bennett. D. J.; Blum, P. S.; Codd, E. E.; Maryanoff, C. A.; Ortegon, M. E.; Renzi, M. J.; Scott, M. K.; Shank, R. P.; Vaught, J. L. A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/α1A-adrenergic affinity and a low potential for extrapyramidal effects. J. Med. Chem., 1994, 37, 1060-1062. (Pubitemid 24145366)
183. Al-Shamahi, A.; Kirkham, K.; Hookes, L. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases. IDrugs, 2009, 12, 734-737.
184. McCreary, A. C.; Glennon, J. C.; Ashby, C. R.; Meltzer, H. Y.; Li, Z.; Reinders, J. H.; Hesselink, M. B.; Long, S. K.; Herremans, A. H.; van Stuivenberg, H.; Feenstra, R. W.; Kruse, C. G. SLV313 (1- (2,3-dihydro-benzo[1, 4]dioxin-5-yl)-4-[5-(4-fluoro- phenyl) - pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology, 2007, 32, 78-94. (Pubitemid 44967786)
185. Sumiyoshi, T.; Higuchi, Y. Facilitative effect of serotonin (1A) receptor agonists on cognition in patients with schizophrenia. Curr. Med. Chem., 2013, 20(3), 357-362.